Noura Abul-Husn, MD, PhD
Associate Professor of Medicine and Genetics
Chief of the Division of Genomic Medicine
Department of Medicine
Clinical Director, Institute for Genomic Health
Icahn School of Medicine at Mount Sinai
Dr. Abul-Husn is a physician-scientist working to uncover the clinical impact of human genetic variation in diverse populations and drive the equitable implementation of genomic medicine. Her scientific contributions include pioneering genome-first approaches to provide novel clinical insights and inform therapeutic discovery. She is an expert at leveraging large-scale genomic data linked to electronic health records, and her work has been published in leading journals, including Science, Cell, and the New England Journal of Medicine. In her current role, Dr. Abul-Husn directs a genomic screening program for medically actionable conditions in the ancestrally diverse BioMe Biobank, and is leading efforts to integrate genomic risk information into clinical care for diverse patient populations. She participates in national consortium-based genomic medicine research, and is a principal investigator in the eMERGE (electronic Medical Records and Genomics) Network. Dr. Abul-Husn directs a new Genomic Health Clinic to provide the clinical infrastructure for genomic risk communication, and has initiated a Genomic Medicine Track for Internal Medicine residents to expand genomics knowledge across medical specialties. 


Carlos A. Bacino, MD
Associate Professor, Department of Molecular and Human Genetics
Baylor College of Medicine
Dr. Bacino is involved in the diagnosis and management of patients with birth defects and a variety of genetic disorders. He participates in subspecialty clinics such as the Skeletal Dysplasia and Craniofacial Clinics. As the Medical Director of the Kleberg Cytogenetics Laboratory, he has a particular interest in structural chromosomes abnormalities and genomic disorders, as well as the mechanism of origin of these chromosome anomalies. In the area of clinical genetics, he is actively involved in the diagnosis and management of pediatric patients with birth defects and rare genetic disorders. He is also interested in the clinical aspect of bone disorders and participate at the Skeletal Dysplasia Clinic at TCH. Currently, he supervises and trains medical students, residents, and fellows. As the Medical Director of the BMGL Cytogenetics Laboratory, he has a particular interest in structural chromosomes abnormalities and genomic disorders (contiguous gene deletion/duplication syndromes).


Amy Brower, PhD
Project Manager for the Newborn Screening Translational Research Network
American College of Medical Genetics and Genomics (ACMG)
In her role at the American College of Medical Genetics and Genomics (ACMG), Dr. Brower’s work focuses on creating informatics tool and an expert network of clinicians, researchers sand public health teams to advance research in newborn screening. Dr. Brower was a member of the Human Genome Project Team and spent a decade in industry developing molecular diagnostic tools.  She is a former member of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (ADHDNC) and a member of the Follow-up and Treatment Subcommittee and co-chair of its Quality Measures and Health Outcome Workgroup. She serves several advisory boards focused on incorporating genomic medicine into clinical care to improve health outcomes. Dr. Brower lectures on genomics, neuroscience, embryology and child development for doctoral level programs.


Susan Klugman, MD, FACOG, FACMG
Director, Reproductive and Medical Genetics and Program Director, Medical Genetics and Genomics Residency
Professor, Obstetrics and Gynecology and Women’s Health
Albert Einstein College of Medicine.
Dr. Klugman’s clinical focus is on the evaluation of patients and families at risk for genetic disorders during pregnancy or preconception, including prenatal diagnosis and consultation for patients undergoing assisted reproductive technologies. She also provides evaluations for patients at risk for hereditary cancer syndromes. Dr. Klugman’s research focuses on novel methods for prenatal screening, testing and diagnosis as well as the assessment of new modalities for diagnoses and treatment of hereditary cancer syndromes. Her work has been published in peer-reviewed journals, book chapters, and other print publications. She has completed six year terms on both the Committee on Genetics of the American Board of Obstetrics and Gynecology and the Residency Review Committee for Medical Genetics for the Accreditation Council of Graduate Medical Education. In 2021 she will serve as President Elect and 2023, President of the organization.


Sharon E. Plon, MD, PhD, FACMG
Professor, Departments of Pediatrics and Molecular and Human Genetics
Baylor College of Medicine
Dr. Plon founded in 1995 and serves as chief of the Cancer Genetics Clinic in the Texas Children’s Cancer Center. Her translational research has included studying physician interpretation of genetic test results as well as laboratory research on the identification of novel childhood cancer susceptibility genes. Drs. Plon and D. William Parsons are principal investigators of the NHGRI-funded project on the incorporation of genome sequencing into the care of newly diagnosed childhood cancer patients.  Dr. Plon is also one of the principal investigators of the Clinical Genomics Resource (ClinGen). She served as the chair of the NHGRI/NBCI ClinGen Executive Committee in 2014. She is a diplomat of the American Board of Medical Genetics in the field of Clinical Genetics. Dr. Plon has served on the steering committee of the Whole Genome Laboratory and Cancer Genetics Laboratory since 2011.


Melissa Wasserstein, MD
Chief, Division of Pediatric Genetic Medicine, CHAM
Associate Professor of Pediatrics and of Genetics,
Albert Einstein College of Medicine.
Dr. Wasserstein is NIH-funded clinical researcher whose work focuses on evaluating the safety and effectiveness of novel treatments for patients with inborn errors of metabolism. Currently, Dr. Wasserstein is leading the U.S.’ largest pilot newborn screening program for multiple disorders, including Sanfilippo syndrome type A and type B, recently launched across eight hospitals in New York. The new screening test — called ScreenPlus – will expand the current newborn testing program to include 14 additional disorders not currently on New York state’s routine infant screening panel. This pilot program will provide critical information about whether these screening methods can be added to routine newborn-screening panels nationwide. Prior to joining CHAM, Dr. Wasserstein was Director of the Program for Inherited Metabolic Diseases at Mount Sinai Health System.